NCT00006473: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Completed | 2 | 72 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP | National Cancer Institute (NCI) | Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia | 02/06 | | | |
NCT01626664: KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) |
|
|
| Completed | 2 | 71 | Europe, US, RoW | KW-0761, mogamulizumab, POTELIGEO®, Pralatrexate, Folotyn, gemcitabine plus oxaliplatin, Gemzar, Eloxatin, GemOx, DHAP, Decadron, Dexasone, Baycadron, Platinol, Depocyt, Ara-C | Kyowa Kirin, Inc. | Adult T-cell Leukemia-Lymphoma | 08/15 | 02/18 | | |
